세계의 종양 혈액검사 시장 보고서(2025년)

Tumor blood testing is a diagnostic technique that analyzes a blood sample to identify cancer-related biomarkers. It primarily detects genetic material released by tumors, such as circulating tumor DNA (ctDNA), providing a minimally invasive alternative to traditional tissue biopsies for cancer detection and monitoring. This approach enables earlier diagnosis, continuous disease monitoring, and more informed treatment decisions.

The primary types of tests in the tumor blood testing market include circulating tumor cell (CTC) tests, circulating tumor DNA (ctDNA) tests, exosome-based tests, and others. CTC tests detect and analyze cancer cells that have detached from a primary tumor and are circulating in the bloodstream. Key technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray-based testing, mass spectrometry, and immunoassays. Tumor blood testing is applied to various cancers, including breast, colorectal, lung, prostate, and melanoma. Major applications include early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Primary end-users comprise hospitals, diagnostic laboratories, research institutes, and other healthcare organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The tumor blood testing market research report is one of a series of new reports from The Business Research Company that provides tumor blood testing market statistics, including tumor blood testing industry global market size, regional shares, competitors with a tumor blood testing market share, detailed tumor blood testing market segments, market trends and opportunities, and any further data you may need to thrive in the tumor blood testing industry. The tumor blood testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor blood testing market size has grown rapidly in recent years. It will grow from $5.27 billion in 2024 to $5.98 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. Growth in the historic period was driven by increasing research in genomics and proteomics, rising patient demand for rapid test results, development of targeted therapies requiring companion diagnostics, the growing trend of decentralized diagnostics, and higher patient preference for home-based sample collection.

The tumor blood testing market size is expected to see rapid growth in the next few years. It will grow to $9.83 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. Growth in the forecast period is expected to be supported by wider use of point-of-care testing solutions, increased clinical validation of novel blood tests, rising government and private funding for cancer research, greater availability of high-sensitivity tumor biomarkers, and growing patient preference for minimally invasive procedures. Key trends anticipated for the forecast period include innovations in multi-cancer early detection (MCED) tests, advancements in companion diagnostics, applications of synthetic biology in diagnostics, integration of blockchain for data security, and adoption of robotics in laboratory processes.

The rising occurrence of cancer is expected to contribute to the growth of the tumor blood testing market in the near future. An aging population and increased exposure to risk factors such as unhealthy diets, tobacco use, and environmental pollution are leading to a higher number of cancer cases. This is creating greater demand for early detection methods. Tumor blood testing offers a less invasive approach for identifying cancer at an early stage by detecting specific biomarkers in the blood. This allows for earlier diagnosis, timely treatment, better patient outcomes, and continuous monitoring of disease progression as well as therapy effectiveness. For example, in May 2024, the National Cancer Institute, a government organization in the United States, reported that as of January 2022, an estimated 18.1 million cancer survivors were living in the country, with this number expected to grow to 26 million by 2040. As a result, the increasing number of cancer cases is contributing to the expansion of the tumor blood testing market.

Leading companies in the tumor blood testing market are prioritizing the development of new technologies, including non-invasive liquid biopsy techniques, to improve early cancer detection, monitor how patients respond to treatment, and track disease progression more effectively. These liquid biopsy methods are diagnostic tools that identify and examine cancer-related biomarkers found in body fluids, offering a safer and more convenient option compared to traditional tissue biopsies. For instance, in February 2024, Delfi Diagnostics, a biotechnology company based in the United States, partnered with Immunocore Holdings plc, a biotechnology company based in the United Kingdom, to introduce the DELFI-Tumor Fraction assay. This blood test evaluates fragments of cell-free DNA present in the bloodstream to determine tumor levels and how the body is responding to treatment. This liquid biopsy, which relies on fragmentome analysis, serves as a non-invasive and cost-efficient alternative to conventional diagnostic procedures, requiring only a small amount of plasma and delivering results within two weeks.

In August 2025, Exact Sciences Corp., a diagnostics and biotechnology firm based in the United States, obtained the rights to a blood-based colon cancer screening test developed by Freenome Holdings Inc. for an undisclosed sum. With this acquisition, Exact Sciences Corp aims to strengthen its position in the field of early cancer detection and enhance its technological offerings by integrating Freenome Holdings Inc.'s advanced platform, which uses multiple types of data along with artificial intelligence to support blood testing. Freenome Holdings Inc. is a biotechnology company located in the United States that is focused on developing blood-based diagnostics to identify cancer at an early stage.

Major players in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

North America was the largest region in the tumor blood testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tumor blood testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tumor blood testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor blood testing market consists of revenues earned by entities by providing services such as liquid biopsy testing services, early cancer detection services, clinical trial support services, genetic mutation profiling services, and cancer biomarker screening services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor blood testing market also includes sales of exosome isolation kits, immunoassay kits, microfluidic devices, epigenetic assay kits, and protein biomarker panels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tumor Blood Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tumor blood testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tumor blood testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor blood testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Circulating Tumor Cells (CTC) Tests; Circulating Tumor DNA (CtDNA) Tests; Exosome-Based Tests; Other Test Types
• 2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing; Next-Generation Sequencing; Microarray-Based Testing; Mass Spectrometry; Immunoassays
• 3) By Cancer Type: Breast Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer; Melanoma
• 4) By Application: Early Cancer Screening; Therapy Selection; Treatment Monitoring; Recurrence Monitoring
• 5) By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End-Users
• Subsegments:
• 1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells; Enumeration Of Tumor Cells; Characterization Of Tumor Cells
• 2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA; Methylation Analysis Of Tumor DNA; Copy Number Variation Analysis Of Tumor DNA; Fragmentation Analysis Of Tumor DNA
• 3) By Exosome-Based Tests: Protein Profiling Of Exosomes; RNA Profiling Of Exosomes; Lipid Profiling Of Exosomes; Surface Marker Analysis Of Exosomes
• 4) By Other Tests: Circulating RNA Tests; Tumor Educated Platelet Tests; Protein Biomarker Panels; Multiomics Blood Tests; Immuno Oncology Biomarker Tests
• Companies Mentioned: Bio-Techne Corporation; Roche Holding AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Illumina Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Natera Inc.; Myriad Genetics Inc.; Neogenomics Laboratories Inc.; Guardant Health Inc.; Foundation Medicine Inc.; Adaptive Biotechnologies Corporation; Freenome Holdings Inc.; Grail Inc.; Personal Genome Diagnostics Inc.; Exosome Diagnostics Inc.; Agena Bioscience Inc.; Menarini Silicon Biosystems S.p.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tumor Blood Testing Market Characteristics

3. Tumor Blood Testing Market Trends And Strategies

4. Tumor Blood Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Tumor Blood Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tumor Blood Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tumor Blood Testing Market Growth Rate Analysis
• 5.4. Global Tumor Blood Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tumor Blood Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tumor Blood Testing Total Addressable Market (TAM)

6. Tumor Blood Testing Market Segmentation

• 6.1. Global Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Circulating Tumor Cells (CTC) Tests
• Circulating Tumor DNA (CtDNA) Tests
• Exosome-Based Tests
• Other Test Types
• 6.2. Global Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR)-Based Testing
• Next-Generation Sequencing
• Microarray-Based Testing
• Mass Spectrometry
• Immunoassays
• 6.3. Global Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Melanoma
• 6.4. Global Tumor Blood Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring
• 6.5. Global Tumor Blood Testing Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Other End-Users
• 6.6. Global Tumor Blood Testing Market, Sub-Segmentation Of Circulating Tumor Cells Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isolation Of Tumor Cells
• Enumeration Of Tumor Cells
• Characterization Of Tumor Cells
• 6.7. Global Tumor Blood Testing Market, Sub-Segmentation Of Circulating Tumor DNA Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mutation Detection Of Tumor DNA
• Methylation Analysis Of Tumor DNA
• Copy Number Variation Analysis Of Tumor DNA
• Fragmentation Analysis Of Tumor DNA
• 6.8. Global Tumor Blood Testing Market, Sub-Segmentation Of Exosome-Based Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Profiling Of Exosomes
• RNA Profiling Of Exosomes
• Lipid Profiling Of Exosomes
• Surface Marker Analysis Of Exosomes
• 6.9. Global Tumor Blood Testing Market, Sub-Segmentation Of Other Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Circulating RNA Tests
• Tumor Educated Platelet Tests
• Protein Biomarker Panels
• Multiomics Blood Tests
• Immuno Oncology Biomarker Tests

7. Tumor Blood Testing Market Regional And Country Analysis

• 7.1. Global Tumor Blood Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tumor Blood Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tumor Blood Testing Market

• 8.1. Asia-Pacific Tumor Blood Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tumor Blood Testing Market

• 9.1. China Tumor Blood Testing Market Overview
• 9.2. China Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tumor Blood Testing Market

• 10.1. India Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tumor Blood Testing Market

• 11.1. Japan Tumor Blood Testing Market Overview
• 11.2. Japan Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tumor Blood Testing Market

• 12.1. Australia Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tumor Blood Testing Market

• 13.1. Indonesia Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tumor Blood Testing Market

• 14.1. South Korea Tumor Blood Testing Market Overview
• 14.2. South Korea Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tumor Blood Testing Market

• 15.1. Western Europe Tumor Blood Testing Market Overview
• 15.2. Western Europe Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tumor Blood Testing Market

• 16.1. UK Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tumor Blood Testing Market

• 17.1. Germany Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tumor Blood Testing Market

• 18.1. France Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tumor Blood Testing Market

• 19.1. Italy Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tumor Blood Testing Market

• 20.1. Spain Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tumor Blood Testing Market

• 21.1. Eastern Europe Tumor Blood Testing Market Overview
• 21.2. Eastern Europe Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tumor Blood Testing Market

• 22.1. Russia Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tumor Blood Testing Market

• 23.1. North America Tumor Blood Testing Market Overview
• 23.2. North America Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tumor Blood Testing Market

• 24.1. USA Tumor Blood Testing Market Overview
• 24.2. USA Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tumor Blood Testing Market

• 25.1. Canada Tumor Blood Testing Market Overview
• 25.2. Canada Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tumor Blood Testing Market

• 26.1. South America Tumor Blood Testing Market Overview
• 26.2. South America Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tumor Blood Testing Market

• 27.1. Brazil Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tumor Blood Testing Market

• 28.1. Middle East Tumor Blood Testing Market Overview
• 28.2. Middle East Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tumor Blood Testing Market

• 29.1. Africa Tumor Blood Testing Market Overview
• 29.2. Africa Tumor Blood Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tumor Blood Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tumor Blood Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tumor Blood Testing Market Competitive Landscape And Company Profiles

• 30.1. Tumor Blood Testing Market Competitive Landscape
• 30.2. Tumor Blood Testing Market Company Profiles
  • 30.2.1. Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Tumor Blood Testing Market Other Major And Innovative Companies

• 31.1. Illumina Inc.
• 31.2. Sysmex Corporation
• 31.3. Bio-Rad Laboratories Inc.
• 31.4. Natera Inc.
• 31.5. Myriad Genetics Inc.
• 31.6. Neogenomics Laboratories Inc.
• 31.7. Guardant Health Inc.
• 31.8. Foundation Medicine Inc.
• 31.9. Adaptive Biotechnologies Corporation
• 31.10. Freenome Holdings Inc.
• 31.11. Grail Inc.
• 31.12. Personal Genome Diagnostics Inc.
• 31.13. Exosome Diagnostics Inc.
• 31.14. Agena Bioscience Inc.
• 31.15. Menarini Silicon Biosystems S.p.A.

32. Global Tumor Blood Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tumor Blood Testing Market

34. Recent Developments In The Tumor Blood Testing Market

35. Tumor Blood Testing Market High Potential Countries, Segments and Strategies

• 35.1 Tumor Blood Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tumor Blood Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tumor Blood Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer